Necrotizing External Otitis : Study in a Regional Bone and Joint Infection Reference Center

Overview

The malignant external otitis is a rare disease which arises more frequently at the elderly and the diabetics patients. To our knowledge, there are few data and it is not wellc known byclinicians. Nevertheless it exposes to neurological complications potentially serious and crippling.

Full Title of Study: “Necrotizing External Otitis : Study in a Regional Bone and Joint Infection”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: January 31, 2018

Interventions

  • Other: necrotizing external otitis
    • description of necrotizing external otitis

Arms, Groups and Cohorts

  • Necrotizing external otitis
    • description of necrotizing external otitis

Clinical Trial Outcome Measures

Primary Measures

  • Rate of necrotizing external otitis
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • description of necrotizing external otitis: patients, profile of the bacterium, medical and chirurgical treatment, rate

Secondary Measures

  • Rate of Treatment Failure
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor.
  • Duration of antibiotics
    • Time Frame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
    • Description of the strategies of antibiotic treatments used (double-agent therapy, monotherapy, duration)

Participating in This Clinical Trial

Inclusion Criteria

  • patients having had necrotizing external otitis and managed at the Lyon Bone and joint infection refence Center Exclusion Criteria:

  • none

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 95 Years

Investigator Details

  • Lead Sponsor
    • Hospices Civils de Lyon
  • Provider of Information About this Clinical Study
    • Principal Investigator: EugĂ©nie MABRUT, Clinical Reseacrh Assistant – Hospices Civils de Lyon
  • Overall Official(s)
    • Tristan Ferry, Md, PhD, Principal Investigator, Hospices Civils de Lyon

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.